Search Results - Therapeutics

HOME SEARCH RSS
60 Results Sort By:
Ibuprofen hybrid conjugates as potential anti-inflammatory and analgesic agents
The current state of the art: Nonsteroidal anti-inflammatory drugs (NSAIDs) have broad therapeutic use that ranges from the treatment for fever, inflammation, and mild pain to severe chronic inflammatory disorders. NSAIDs mainly act by COX 1 inhibition, the key enzymes capable of the conversion of arachidonic acid to prostaglandins. Therefore, the...
Published: 8/26/2020   |   Inventor(s): Siva Panda
Keywords(s):  
Category(s): Therapeutics
Pyrazinoic acid-isoniazid hybrid conjugates’ antimycobacterial and antibacterial properties
The current state of the art: Tuberculosis is one of the top 10 causes of death worldwide. Patients are treated for two months with first-line drugs including isoniazid, rifampin, pyrazinamide, and ethambutol, followed by another four months of isoniazid and rifampin alone. The problems of the current art: However, the multidrug-resistant disease...
Published: 8/26/2020   |   Inventor(s): Siva Panda
Keywords(s):  
Category(s): Therapeutics
CAR-T cell compositions and use in hepatocellular carcinoma
The current state of the art The majority of liver cancers, the 2nd leading cause of cancer death among adult men, are hepatocellular carcinoma (HCC). About 70-80% HCC tumors, but not normal hepatocytes, express glypican 3 (GPC3), a cell surface antigen. Thus, GPC3 might be a great target for HCC immunotherapy, especially chimeric antigen receptor-modified...
Published: 5/8/2020   |   Inventor(s): Yukai He, Xiaotao Jiang, Leidy Caraballo Galva, Xiangguo Qiu
Keywords(s):  
Category(s): Therapeutics
Deformylase, a new drug to improve survival in Sepsis
The Current State of The Art Sepsis is the world’s third leading cause of death and the leading cause of death for infants and children. Sepsis management is one of the most expensive in-patient hospital care. The current treatments include antibiotics and IV fluid to reduce inflammation and control blood pressure. The Problem of the Current...
Published: 5/1/2020   |   Inventor(s): Camilla Wenceslau, Patricia Martinez-Quinones, Clinton Webb, Cameron McCarthy
Keywords(s):  
Category(s): Therapeutics
Mitochondrial-Targeted Peptide Modulators of Delta Protein Kinase C Interaction with the d-subunit of F1Fo ATP Synthase/ATPase as Therapeutics Against Cardiac Injury
Current State of the Art: Current clinical therapy for heart attack victims focuses on the rapid restoration of blood flow by thrombolysis, angioplasty, stenting and when appropriate surgical coronary artery bypass grafts. Problems with the Current Art: The majority of cardiac cell death associated with a heart attack actually occurs during the...
Published: 4/29/2020   |   Inventor(s): John Johnson, Tiffany Tuyen Nguyen, Mourad Ogbi
Keywords(s): Cardiovascular, Heart Attack, Therapeutics
Category(s): Therapeutics
Crosslinking proteins to RBCs (protein-RBCs) with EDC can be improved with sulfo-NHS +/- sulfo-NHS-acetate
Intravenous infusion of protein/peptide antigens linked to lymphocytes with ethylene carbodiimide (EDC) is a highly efficient method for inducing peripheral, antigen-specific T cell tolerance for the treatment of autoimmune disease. Likewise, red blood cells (RBC) can be used to deliver protein/peptide antigens for treatment of autoimmune disease. EDC...
Published: 4/29/2020   |   Inventor(s): Ryan Jajosky, Rafal Pacholczyk, Gurmukh Singh
Keywords(s):  
Category(s): Therapeutics
Modified Green Tea Polyphenol EGCG and EGCG-ester Inhibit Endospores
Modified Green Tea Polyphenol EGCG and EGCG-ester Inhibit EndosporesResearchers at Augusta University have invented skin-friendly compositions and methods for killing, inactivating, or otherwise reducing the bacterial endospores by using an effective amount of the green tea EGCG or its derivatives. EGCG research shows clear application for a hand sanitizer...
Published: 4/28/2020   |   Inventor(s): Stephen Hsu, Lee Lee, Tin-Chun Chu
Keywords(s):  
Category(s): Therapeutics
11-Nonyloxy-Undec-8(Z)-Eonic Acid Derivatives as Therapy for Renal and Cardiovascular Diseases
Title: Epoxy Lipid Mimics as Lead Compounds for Endothelial Dysfunction Current State of the Art:  Endothelial cell dysfunction is an underlying cause of vascular disease and is also found in patients with coronary artery disease, diabetes, high cholesterol and high blood pressure (hypertension). Available treatments include nonsteroidal anti-inflammatory...
Published: 4/28/2020   |   Inventor(s): John Imig, John Falck
Keywords(s): Endothelial, Epoxy, Lipids, Renal Disease, Vascular Disease
Category(s): Therapeutics
Use of JNK Signaling and JNK Inhibitors for the Treatment of Spinal Muscular Atrophy
Current State of the Art: SMA is a devastating neurodegenerative disorder with progressive muscle weakness and loss of motor control due to the loss of neurons in the spinal cord. SMA affects approximately 4 out of every 100,000 people. Children born with SMA Type I, die within 2 years of birth. Those diagnosed with Type II and III can live on...
Published: 4/28/2020   |   Inventor(s): Laxman Gangwani
Keywords(s): Muscular Atrophy, Spinal, Therapeutics
Category(s): Therapeutics
Treatment and Prevention of Age-Related Muscle Wasting (Sarcopenia)
TECH ID: 2010-029 Title: Leptin and derivatives for altering muscle mass Current State of the Art: Muscling wasting is the progressive loss of muscle mass, typically seen in the elderly (sarcopenia), in individuals on low calorie diets and or struggling with a serious illness including cancer (Cachexia). This excessive loss of muscle can lead to fragility,...
Published: 4/28/2020   |   Inventor(s): Mark Hamrick
Keywords(s):  
Category(s): Therapeutics
1 2 3 4 5 6 
© 2020. All Rights Reserved. Powered by Inteum